Idera Pharmaceuticals, Inc.
TLR9 MODULATORS FOR TREATING CANCER

Abstract:

The present disclosure relates to methods for treating cancer in patients having low expression of MHC Class I genes, and in patients having increased serum levels of PD-L2 by administration of a TLR9 agonist.